Management of the neovascular choroidal membrane secondary to ocular toxoplasmosis
| Autor: | E. Martín García, J.J. Chávarri García, B. Jiménez del Rio, S.M. Guallar Leza, L. Rodríguez Vicente, J.L. del Río Mayor |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
genetic structures business.industry Chorioretinitis General Medicine Fundus (eye) medicine.disease eye diseases Congenital toxoplasmosis Toxoplasmosis 03 medical and health sciences Left eye 0302 clinical medicine Ophthalmology Decreased Visual Acuity Choroidal neovascular membrane 030221 ophthalmology & optometry Medicine sense organs 030212 general & internal medicine Macular scar business |
| Zdroj: | Archivos de la Sociedad Española de Oftalmología (English Edition). 95:90-93 |
| ISSN: | 2173-5794 |
| DOI: | 10.1016/j.oftale.2019.11.002 |
| Popis: | A 12-year-old patient diagnosed with congenital toxoplasmosis, with no systemic treatment at the time, who presented with a decreased visual acuity (VA) in his left eye (LE). On examination, VA in the LE was 0.05 and the fundus examination revealed a focus of chorioretinitis adjacent to a pigmented macular scar, as well as a large associated subretinal haemorrhage. After confirming the diagnosis of choroidal neovascular membrane secondary to ocular toxoplasmosis, treatment was started with systemic anti-toxoplasmosis drugs and two anti-VEGF intravitreal injections separated by one month. Finally, the patients had a VA in LE of 0.4, with reabsorption of the haemorrhage, leaving an inactive pigmented macular scar. The use of anti-VEGF intravitreal injections in cases of ocular toxoplasmosis has been associated with a reactivation of old lesions, so the prophylactic use of oral anti-toxoplasmosis drugs is recommended in these cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect